Geovax Labsincis A Clinical Stage Biotechnology Company Based In Atlantageorgiafounded In 2000The Company Specializes In Developing Vaccines And Immunotherapies Targeting Infectious Diseases And Cancersgeovax Is Committed To Innovation And Collaboration In Its Product Development Efforts The Company S Product Pipeline Includes A Next Generation Covid 19 Vaccine In Preclinical Stagesan Mva Vlp Hiv Vaccine Currently In Phase 2 Clinical Trialsand Cancer Immunotherapies For Advanced Head And Neck Cancer And Various Solid Tumorsadditionallygeovax Is Working On Preventive Vaccines For Diseases Such As Mpoxsmallpoxebolamalariaand Zika Virusthey Utilize A Patented Modified Vaccinia Ankara Virus Like Particlemva Vlptechnology To Stimulate Immune Responses Safely Geovax Aims For Worldwide Distribution Through Strategic Partnerships And Has Received Funding From The National Institutes Of Health And Private Investorsas Of 2024The Company Has 22 Employees And Is Publicly Traded On Nasdaq Under The Symbol Govx
